Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003592 · ClinicalTrials.gov registry record · Phase 3
Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer
A Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 230
- Enrollment target
NCT00003592 is a Phase 3 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 230 participants.
The verdict
NCT00003592, a Phase 3 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 230 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether methotrexate or paclitaxel is more effective in treating patients with advanced head and neck cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of methotrexate with that of paclitaxel in treating patients who have advanced head and neck cancer that cannot be treated with cisplatin.
Interventions
- DRUG paclitaxel
- DRUG methotrexate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 1999-04-22 |
| Est. Completion | 2004-03-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003592
The ClinicalTrials.gov registry entry for NCT00003592 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which paclitaxel is the first listed.
NCT00003592 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003592 about?
NCT00003592 is a clinical study titled "Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether methotrexate or paclitaxel is more effective in treating patients with advanced head and neck cancer. PURPOSE: Randomized phase III trial to compare th...
What is the current status of trial NCT00003592?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 230 participants. The study started on 1999-04-22. Estimated completion is 2004-03-02.
What interventions are being tested in trial NCT00003592?
The interventions under investigation include: paclitaxel (DRUG), methotrexate (DRUG).
Who is sponsoring clinical trial NCT00003592?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.